Uncovering the true cost of your pharmacy benefit

Comparing the cost of pharmacy benefit managers (PBMs) can be a challenge. That’s because not all PBMs start with the same net cost before subtracting discounts and rebates. What’s more, they may present it all in complex, confusing spreadsheets. The good news is there is a single number you can look at when comparing PBMs: your net cost per member per month, also known as PMPM.

TRANSPARENT SAVINGS

Consistently delivering low PMPM

*Than national benchmarks

COMPREHENSIVE STRATEGY

Employing multiple drug management methods

The most effective PBMs help deliver the best patient outcomes at a lower cost. Prime takes a holistic approach to help ensure our formularies include the best options, promote evidence-based biosimilars and offer industry-leading utilization programs.

Formulary management

Some PBMs prioritize high-priced drugs over lower-cost options due to manufacturer rebates. But Prime focuses on the lowest-cost, most clinically effective options to keep costs low and improve health outcomes.

Specialty drug management

Prime is focused on improving access to low-cost specialty drugs by developing innovative products and driving the use of evidence-based biosimilars.

Utilization management (UM)

We help our clients choose UM programs that not only provide their members safe, cost-effective medicines, but also address industry-wide problems like inappropriate use and fraud, waste and abuse.

Related news

Perspectives

June 14, 2024

High-Cost Therapy Profile: June 2024

Detailed information about Imetelstat Intravenous (IV)

Perspectives

June 14, 2024

July 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market

Perspectives

May 30, 2024

Drug Approvals Monthly Update: May 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

1 Milliman survey, 2020; commercial business including fully insured and self-insured

2 Prime Therapeutics internal data, 2017; savings based on actual savings reports, inclusive of all formulary savings

3 U.S. Food and Drug Administration, and Federal Trade Commission. (2020, February 3). FDA and FTC announce new efforts to further deter anti-competitive business practices, support competitive market for biological products to help Americans [Press release]. https://www.fda.gov/news-events/press-announcements/fda-and-ftc-announce-new-efforts-further-deter-anti-competitive-business-practices-support

4 Watanabe, J. H., McInnis, T., & Hirsch, J. D. (2018, March 26). Cost of prescription drug-related morbidity and mortality. Annals of Pharmacotherapy, 52(9). https://journals.sagepub.com/doi/10.1177/1060028018765159